Compare CEVA & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CEVA | ABSI |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.9M | 577.4M |
| IPO Year | 2000 | 2021 |
| Metric | CEVA | ABSI |
|---|---|---|
| Price | $22.77 | $3.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $34.00 | $7.98 |
| AVG Volume (30 Days) | 570.6K | ★ 3.4M |
| Earning Date | 02-12-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,530,000.00 | $2,815,000.00 |
| Revenue This Year | $4.34 | $10.72 |
| Revenue Next Year | $13.26 | $437.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.55 | N/A |
| 52 Week Low | $18.23 | $2.01 |
| 52 Week High | $38.94 | $6.33 |
| Indicator | CEVA | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 52.93 | 49.82 |
| Support Level | $21.10 | $3.40 |
| Resistance Level | $24.01 | $4.16 |
| Average True Range (ATR) | 0.65 | 0.20 |
| MACD | 0.28 | 0.02 |
| Stochastic Oscillator | 65.61 | 24.20 |
CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived primarily from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.